

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.7	80.6	(32.3-166.1)	Male	14	5.7	246.5	(134.7-413.7)
Female	3	2.6	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.4	(32.0-231.9)
Female	36	31.8	113.3	(79.4-156.9)	Female	4	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	8	9.5	84.5	(36.4-166.6)	<u>Ovary</u>				
Female	6	7.8	77.2	(28.2-168.1)	Female	3	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	33	32.9	100.4	(69.1-140.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.6	125.5	(50.3-258.7)
Male	0	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	9	7.5	120.5	(55.0-228.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	109	119.2	91.5	(75.1-110.4)
Female	1	0.9	nc	(nc-nc)	Female	95	103.7	91.7	(74.1-112.0)
<u>Lung and Bronchus</u>									
Male	11	16.1	68.2	(34.0-122.1)					
Female	9	15.0	60.2	(27.5-114.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	20.6	92.0	(55.4-143.7)	Male	29	13.4	216.3	(144.8-310.7)
Female	7	8.4	83.1	(33.3-171.3)	Female	18	11.6	155.7	(92.3-246.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.9	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	6	3.8	156.2	(57.0-340.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	18	11.9	151.6	(89.8-239.7)
Female	95	93.4	101.7	(82.3-124.4)	Female	8	11.7	68.3	(29.4-134.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	12	10.1	118.5	(61.2-207.0)
<u>Colon / Rectum</u>					Female	4	5.0	nc	(nc-nc)
Male	24	22.5	106.7	(68.4-158.8)	<u>Ovary</u>				
Female	27	24.7	109.4	(72.1-159.2)	Female	5	8.3	60.2	(19.4-140.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.7	104.4	(38.1-227.3)	Male	9	7.4	121.0	(55.2-229.7)
Female	1	1.7	nc	(nc-nc)	Female	9	8.4	107.0	(48.8-203.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	85	76.2	111.6	(89.1-138.0)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.9	122.4	(44.7-266.3)
Male	9	11.8	76.5	(34.9-145.2)	Female	4	3.2	nc	(nc-nc)
Female	3	7.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.3	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	11	5.2	212.4	(105.9-380.1)
<u>Leukemia</u>					Female	21	15.7	133.6	(82.7-204.2)
Male	5	8.1	61.6	(19.9-143.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	6.6	nc	(nc-nc)	Female	22	22.3	98.5	(61.7-149.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.6	nc	(nc-nc)	Male	287	280.1	102.5	(91.0-115.0)
Female	4	2.7	nc	(nc-nc)	Female	307	313.9	97.8	(87.2-109.4)
<u>Lung and Bronchus</u>									
Male	22	37.9	58.1	(36.4-87.9)					
Female	40	45.5	87.9	(62.8-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	88	102.1	86.2	(69.1-106.2)	Male	69	62.6	110.3	(85.8-139.6)
Female	46	35.1	130.9	(95.8-174.6)	Female	62	48.3	128.4	(98.4-164.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	24	18.0	133.2	(85.3-198.2)	Male	26	19.9	130.6	(85.3-191.3)
Female	16	15.4	104.0	(59.4-168.9)	Female	18	15.7	114.5	(67.8-180.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.4	nc	(nc-nc)	Male	61	56.2	108.6	(83.1-139.5)
Female	437	375.2	116.5	(105.8-127.9)	Female	53	48.5	109.2	(81.8-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	12.5	79.7	(38.2-146.6)	Male	30	43.2	69.5	(46.9-99.2)
<u>Colon / Rectum</u>					Female	28	20.4	137.2	(91.2-198.3)
Male	92	107.0	86.0	(69.3-105.5)	<u>Ovary</u>				
Female	82	105.9	77.4	(61.6-96.1)	Female	38	33.7	112.6	(79.7-154.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	25.8	42.6	(21.2-76.3)	Male	34	35.0	97.0	(67.2-135.6)
Female	9	6.8	132.7	(60.6-251.9)	Female	51	35.4	143.9	(107.1-189.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	6.9	nc	(nc-nc)	Male	341	320.1	106.5	(95.5-118.4)
Female	3	6.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	20	23.3	85.7	(52.3-132.3)
Male	56	51.6	108.5	(81.9-140.9)	Female	14	13.7	102.3	(55.9-171.7)
Female	21	30.1	69.7	(43.2-106.6)	<u>Testis</u>				
<u>Larynx</u>					Male	11	11.7	93.8	(46.8-167.9)
Male	10	14.8	67.6	(32.4-124.4)	<u>Thyroid</u>				
Female	1	4.5	nc	(nc-nc)	Male	34	22.4	152.1	(105.3-212.5)
<u>Leukemia</u>					Female	81	68.0	119.1	(94.6-148.0)
Male	41	39.5	103.8	(74.5-140.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	28.7	76.6	(48.0-115.9)	Female	91	85.7	106.2	(85.5-130.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	31	32.8	94.4	(64.1-134.0)	Male	1189	1278.0	93.0	(87.8-98.5)
Female	9	11.0	81.5	(37.2-154.7)	Female	1370	1288.7	106.3	(100.8-112.1)
<u>Lung and Bronchus</u>									
Male	130	177.9	73.1	(61.0-86.8)					
Female	158	182.0	86.8	(73.8-101.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	11.2	62.3	(24.9-128.3)	Male	12	8.5	140.6	(72.6-245.7)
Female	2	2.5	nc	(nc-nc)	Female	7	4.3	161.5	(64.7-332.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.8	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.7	104.5	(45.0-205.9)
Female	46	36.0	127.9	(93.6-170.6)	Female	0	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	11	13.9	79.2	(39.5-141.7)	<u>Ovary</u>				
Female	8	7.8	103.1	(44.4-203.2)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.6	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	44	49.3	89.3	(64.9-119.9)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	2.9	205.2	(74.9-446.6)
Male	6	8.1	74.1	(27.1-161.4)	Female	1	1.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.3	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	7.1	112.7	(48.5-222.0)
Male	6	5.1	118.1	(43.1-257.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	7	8.5	82.6	(33.1-170.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.1	nc	(nc-nc)	Male	149	176.5	84.4	(71.4-99.1)
Female	0	0.9	nc	(nc-nc)	Female	113	111.4	101.4	(83.6-121.9)
<u>Lung and Bronchus</u>									
Male	19	21.5	88.5	(53.2-138.2)					
Female	12	14.2	84.3	(43.5-147.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.1	105.4	(62.4-166.5)	Male	6	10.4	57.6	(21.0-125.4)
Female	12	5.9	202.8	(104.6-354.2)	Female	8	7.8	102.5	(44.1-201.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	9.3	129.1	(66.6-225.5)
Female	52	60.6	85.8	(64.1-112.5)	Female	7	8.0	88.0	(35.3-181.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	5	6.9	72.8	(23.5-169.9)
<u>Colon / Rectum</u>					Female	3	3.3	nc	(nc-nc)
Male	27	17.6	153.3	(101.0-223.0)	<u>Ovary</u>				
Female	22	17.3	127.1	(79.7-192.5)	Female	6	5.4	110.4	(40.3-240.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	4.2	191.5	(82.5-377.3)	Male	0	5.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	10	5.9	169.6	(81.2-311.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	51	49.7	102.6	(76.4-134.9)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	155.8	(56.9-339.1)
Male	14	8.3	167.7	(91.6-281.5)	Female	1	2.2	nc	(nc-nc)
Female	2	5.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	0.7	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	10.7	84.4	(38.5-160.1)
Male	6	6.6	90.9	(33.2-197.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.7	107.0	(34.5-249.7)	Female	12	13.7	87.9	(45.4-153.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	5.2	209.6	(104.5-375.1)	Male	230	208.2	110.5	(96.7-125.7)
Female	3	1.8	nc	(nc-nc)	Female	223	210.8	105.8	(92.4-120.6)
<u>Lung and Bronchus</u>									
Male	34	29.7	114.5	(79.3-160.0)					
Female	47	31.4	149.8	(110.0-199.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	28.9	121.1	(84.3-168.4)	Male	18	18.8	95.5	(56.6-151.0)
Female	13	11.5	112.7	(59.9-192.7)	Female	12	15.7	76.3	(39.4-133.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.8	102.9	(37.6-224.1)	Male	5	5.8	85.5	(27.5-199.5)
Female	7	4.9	142.4	(57.1-293.4)	Female	5	5.1	97.9	(31.6-228.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	19	17.0	111.8	(67.3-174.7)
Female	117	123.4	94.8	(78.4-113.6)	Female	17	15.8	107.8	(62.8-172.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.2	119.9	(38.6-279.7)	Male	11	13.7	80.4	(40.1-143.8)
<u>Colon / Rectum</u>					Female	5	6.6	75.8	(24.4-176.9)
Male	29	32.0	90.6	(60.6-130.1)	<u>Ovary</u>				
Female	45	35.2	128.0	(93.3-171.2)	Female	9	10.9	82.4	(37.6-156.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.6	91.9	(36.8-189.4)	Male	13	10.2	127.5	(67.8-218.0)
Female	1	2.2	nc	(nc-nc)	Female	9	11.6	77.4	(35.3-147.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	102	94.6	107.8	(87.9-130.9)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.8	117.1	(50.4-230.8)
Male	19	16.0	118.7	(71.4-185.4)	Female	6	4.6	131.4	(48.0-286.1)
Female	7	9.8	71.2	(28.5-146.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.1	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	10	7.5	133.0	(63.7-244.6)
<u>Leukemia</u>					Female	27	22.4	120.7	(79.5-175.6)
Male	10	11.9	83.7	(40.1-154.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.3	107.0	(51.2-196.8)	Female	22	27.1	81.2	(50.9-123.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	10.0	nc	(nc-nc)	Male	375	380.0	98.7	(89.0-109.2)
Female	3	3.5	nc	(nc-nc)	Female	407	421.2	96.6	(87.5-106.5)
<u>Lung and Bronchus</u>									
Male	36	50.8	70.8	(49.6-98.1)					
Female	52	59.2	87.8	(65.6-115.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	23.1	90.7	(56.1-138.7)	Male	17	16.3	104.1	(60.6-166.7)
Female	7	8.2	85.1	(34.1-175.4)	Female	22	13.4	164.2	(102.9-248.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	108.8	(39.7-236.8)	Male	4	5.0	nc	(nc-nc)
Female	8	4.3	185.5	(79.9-365.6)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	17	14.7	115.6	(67.3-185.1)
Female	103	104.5	98.5	(80.4-119.5)	Female	14	12.2	114.4	(62.5-191.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.0	nc	(nc-nc)	Male	11	12.7	86.9	(43.3-155.5)
<u>Colon / Rectum</u>					Female	8	5.3	151.7	(65.3-298.9)
Male	33	26.9	122.8	(84.5-172.5)	<u>Ovary</u>				
Female	26	26.2	99.4	(64.9-145.6)	Female	5	9.1	55.2	(17.8-128.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.7	119.8	(51.6-236.1)	Male	6	8.6	70.1	(25.6-152.5)
Female	1	1.6	nc	(nc-nc)	Female	10	8.3	120.6	(57.7-221.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	96	88.7	108.3	(87.7-132.2)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.7	nc	(nc-nc)
Male	14	14.8	94.7	(51.7-159.0)	Female	2	3.3	nc	(nc-nc)
Female	6	7.9	75.7	(27.6-164.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.3	nc	(nc-nc)
Male	8	4.0	201.9	(86.9-397.8)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	6	7.3	81.7	(29.8-177.7)
<u>Leukemia</u>					Female	27	21.8	123.9	(81.6-180.2)
Male	6	10.3	58.0	(21.2-126.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.4	67.2	(21.7-156.8)	Female	21	22.9	91.7	(56.8-140.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	9.1	110.0	(52.7-202.4)	Male	347	334.5	103.7	(93.1-115.2)
Female	1	2.7	nc	(nc-nc)	Female	342	339.8	100.7	(90.3-111.9)
<u>Lung and Bronchus</u>									
Male	45	42.9	105.0	(76.6-140.5)					
Female	47	43.8	107.4	(78.9-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	15	20.7	72.5	(40.6-119.6)	Female	4	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Ovary</u>				
Female	5	5.5	91.1	(29.4-212.6)	Female	4	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	18	15.6	115.5	(68.4-182.6)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	64	60.9	105.2	(81.0-134.3)
Female	1	0.6	nc	(nc-nc)	Female	57	68.6	83.1	(63.0-107.7)
<u>Lung and Bronchus</u>									
Male	8	8.2	97.7	(42.1-192.5)					
Female	5	9.6	52.0	(16.8-121.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	14.4	76.5	(38.1-136.9)	Male	16	9.8	163.0	(93.1-264.8)
Female	8	5.2	153.9	(66.3-303.4)	Female	13	8.1	160.7	(85.5-274.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.1	160.3	(51.6-374.0)	Male	4	3.1	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.8	90.6	(39.0-178.4)
Female	76	65.9	115.4	(90.9-144.4)	Female	5	7.6	65.6	(21.1-153.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	5	7.6	66.0	(21.3-154.0)
<u>Colon / Rectum</u>					Female	1	3.3	nc	(nc-nc)
Male	14	16.3	85.6	(46.8-143.7)	<u>Ovary</u>				
Female	15	16.1	93.4	(52.2-154.1)	Female	3	5.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	4.1	217.7	(99.4-413.3)	Male	3	5.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	50	54.8	91.2	(67.7-120.2)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	9	8.9	101.4	(46.2-192.4)	Female	0	2.0	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	5	2.4	205.4	(66.2-479.3)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	16	12.5	128.1	(73.2-208.0)
Male	12	6.0	198.5	(102.4-346.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.3	162.0	(64.9-333.7)	Female	18	14.7	122.4	(72.5-193.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.5	nc	(nc-nc)	Male	201	203.6	98.7	(85.5-113.4)
Female	3	1.7	nc	(nc-nc)	Female	214	211.9	101.0	(87.9-115.5)
<u>Lung and Bronchus</u>									
Male	19	26.5	71.7	(43.1-112.0)					
Female	23	29.0	79.3	(50.2-118.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	29.4	108.7	(74.3-153.5)	Male	12	18.8	63.7	(32.9-111.3)
Female	10	11.1	90.1	(43.1-165.7)	Female	12	16.1	74.4	(38.4-130.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	108.4	(39.6-235.9)	Male	1	6.0	nc	(nc-nc)
Female	6	5.1	118.8	(43.4-258.6)	Female	9	5.0	180.4	(82.3-342.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	15	16.9	89.0	(49.8-146.8)
Female	153	119.9	127.6	(108.2-149.5)	Female	18	15.6	115.6	(68.5-182.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.1	nc	(nc-nc)	Male	15	13.6	110.3	(61.7-182.0)
<u>Colon / Rectum</u>					Female	8	6.5	122.2	(52.6-240.8)
Male	31	31.5	98.5	(66.9-139.8)	<u>Ovary</u>				
Female	35	33.6	104.1	(72.5-144.7)	Female	15	11.0	136.4	(76.3-225.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.9	63.0	(20.3-147.1)	Male	9	10.4	86.9	(39.7-165.0)
Female	5	2.2	232.3	(74.8-542.0)	Female	14	11.2	124.6	(68.0-209.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.2	nc	(nc-nc)	Male	68	103.0	66.0	(51.3-83.7)
Female	2	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.9	72.8	(23.5-169.8)
Male	9	16.2	55.4	(25.3-105.2)	Female	4	4.4	nc	(nc-nc)
Female	9	9.5	94.4	(43.1-179.2)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.0	151.6	(55.3-329.9)
Male	3	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	5	7.3	68.4	(22.0-159.7)
<u>Leukemia</u>					Female	11	23.5	46.7	(23.3-83.6)
Male	13	11.6	112.5	(59.8-192.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.2	108.7	(52.0-199.9)	Female	33	27.6	119.5	(82.2-167.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	10.1	69.4	(27.8-143.0)	Male	313	389.3	80.4	(71.7-89.8)
Female	1	3.5	nc	(nc-nc)	Female	451	413.8	109.0	(99.2-119.5)
<u>Lung and Bronchus</u>									
Male	47	52.8	89.1	(65.5-118.5)					
Female	56	56.9	98.4	(74.3-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	15.2	132.0	(80.6-203.9)	Male	9	9.9	91.0	(41.5-172.7)
Female	9	5.4	166.5	(76.0-316.1)	Female	6	7.7	78.1	(28.5-170.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	8.9	56.0	(18.1-130.7)
Female	71	59.7	118.9	(92.9-150.0)	Female	3	7.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	3	7.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.2	nc	(nc-nc)
Male	12	17.0	70.8	(36.5-123.7)	<u>Ovary</u>				
Female	15	17.0	88.1	(49.3-145.3)	Female	3	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.0	148.7	(54.3-323.6)	Male	5	5.4	92.6	(29.8-216.0)
Female	0	1.0	nc	(nc-nc)	Female	7	5.5	127.3	(51.0-262.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	48	51.3	93.6	(69.0-124.1)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.6	nc	(nc-nc)
Male	6	8.5	70.6	(25.8-153.7)	Female	3	2.2	nc	(nc-nc)
Female	5	4.7	106.0	(34.1-247.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.1	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	8	11.0	72.4	(31.2-142.7)
Male	12	6.2	193.7	(100.0-338.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)	Female	21	13.3	157.7	(97.6-241.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.4	nc	(nc-nc)	Male	172	201.7	85.3	(73.0-99.0)
Female	1	1.7	nc	(nc-nc)	Female	196	202.5	96.8	(83.7-111.3)
<u>Lung and Bronchus</u>									
Male	16	26.8	59.8	(34.1-97.1)					
Female	18	27.5	65.6	(38.8-103.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	15.8	138.8	(87.0-210.2)	Male	8	10.4	77.2	(33.2-152.0)
Female	8	5.3	150.8	(64.9-297.1)	Female	9	8.1	111.5	(50.9-211.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.2	nc	(nc-nc)	Male	8	3.3	245.6	(105.8-484.0)
Female	1	2.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	5	9.3	53.7	(17.3-125.4)
Female	52	62.0	83.9	(62.6-110.0)	Female	7	7.6	91.9	(36.8-189.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	10	7.5	133.4	(63.9-245.3)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	12	17.4	69.0	(35.6-120.5)	<u>Ovary</u>				
Female	27	16.4	164.5	(108.4-239.3)	Female	6	5.5	109.3	(39.9-237.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.2	118.9	(38.3-277.4)	Male	3	5.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	9	5.3	168.9	(77.1-320.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	60	53.1	113.0	(86.2-145.5)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.8	nc	(nc-nc)
Male	20	8.9	224.8	(137.2-347.2)	Female	3	2.1	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	12.4	104.8	(55.7-179.2)
Male	6	6.5	92.2	(33.7-200.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.6	nc	(nc-nc)	Female	20	13.9	143.9	(87.9-222.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.6	nc	(nc-nc)	Male	223	210.0	106.2	(92.7-121.1)
Female	4	1.7	nc	(nc-nc)	Female	220	207.2	106.2	(92.6-121.2)
<u>Lung and Bronchus</u>									
Male	32	28.3	113.2	(77.4-159.8)					
Female	26	27.7	93.8	(61.2-137.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	13	14.2	91.7	(48.8-156.8)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	5	4.6	108.8	(35.1-253.9)	<u>Ovary</u>				
Female	1	3.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.4	45.4	(18.2-93.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	33	56.4	58.5	(40.2-82.1)
Female	1	0.4	nc	(nc-nc)	Female	38	46.1	82.5	(58.4-113.2)
<u>Lung and Bronchus</u>									
Male	3	7.6	nc	(nc-nc)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	16.8	59.4	(28.5-109.3)	Male	14	11.5	121.3	(66.3-203.6)
Female	8	6.3	127.4	(54.9-251.1)	Female	15	9.7	155.2	(86.8-255.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	135.3	(43.6-315.6)	Male	1	3.6	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	7	10.4	67.5	(27.0-139.0)
Female	68	75.9	89.6	(69.5-113.5)	Female	13	9.1	142.5	(75.8-243.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	8	8.9	89.7	(38.6-176.7)
<u>Colon / Rectum</u>					Female	3	4.0	nc	(nc-nc)
Male	27	19.1	141.3	(93.1-205.6)	<u>Ovary</u>				
Female	28	19.5	143.7	(95.5-207.7)	Female	7	6.8	103.6	(41.5-213.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.8	103.8	(33.4-242.2)	Male	9	6.2	146.3	(66.8-277.7)
Female	1	1.2	nc	(nc-nc)	Female	11	6.4	173.1	(86.3-309.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	60	63.0	95.3	(72.7-122.6)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.1	nc	(nc-nc)
Male	13	10.3	126.7	(67.4-216.6)	Female	2	2.5	nc	(nc-nc)
Female	10	5.8	172.8	(82.7-317.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	8	5.0	160.2	(69.0-315.6)
<u>Leukemia</u>					Female	15	14.7	101.8	(57.0-168.0)
Male	6	7.2	83.3	(30.4-181.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.3	112.4	(41.0-244.6)	Female	25	17.4	143.5	(92.8-211.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	6.5	153.5	(73.5-282.3)	Male	239	237.7	100.6	(88.2-114.1)
Female	0	2.1	nc	(nc-nc)	Female	271	249.8	108.5	(96.0-122.2)
<u>Lung and Bronchus</u>									
Male	27	31.0	87.0	(57.3-126.6)					
Female	27	33.0	81.9	(54.0-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.9	85.6	(42.7-153.1)	Male	5	8.1	61.7	(19.9-144.1)
Female	2	4.6	nc	(nc-nc)	Female	14	6.1	229.3	(125.3-384.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.4	250.3	(91.4-544.8)	Male	1	2.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	5	2.1	240.9	(77.6-562.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.3	82.7	(30.2-180.1)
Female	45	50.0	90.1	(65.7-120.5)	Female	11	6.3	173.3	(86.4-310.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.9	85.2	(27.4-198.7)
<u>Colon / Rectum</u>					Female	9	2.7	336.2	(153.4-638.3)
Male	10	13.9	72.1	(34.5-132.6)	<u>Ovary</u>				
Female	8	13.8	57.9	(24.9-114.1)	Female	7	4.4	158.4	(63.5-326.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	4.7	127.7	(46.6-278.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	40	43.3	92.3	(65.9-125.7)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.0	nc	(nc-nc)
Male	6	6.9	86.7	(31.7-188.8)	Female	1	1.8	nc	(nc-nc)
Female	5	4.0	126.2	(40.7-294.4)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	8.1	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.6	nc	(nc-nc)	Female	15	11.5	130.3	(72.9-214.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.4	114.1	(36.8-266.2)	Male	137	167.1	82.0	(68.8-96.9)
Female	1	1.5	nc	(nc-nc)	Female	172	168.9	101.8	(87.2-118.2)
<u>Lung and Bronchus</u>									
Male	13	23.0	56.5	(30.1-96.6)					
Female	15	24.5	61.3	(34.3-101.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	34.0	41.1	(22.5-69.0)	Male	33	21.5	153.5	(105.7-215.6)
Female	13	12.3	105.4	(56.0-180.2)	Female	25	16.4	152.4	(98.6-225.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.3	159.6	(76.4-293.5)	Male	8	6.8	117.2	(50.5-231.0)
Female	7	5.1	137.8	(55.2-283.9)	Female	5	5.4	92.1	(29.7-215.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	22	19.1	115.5	(72.3-174.8)
Female	133	125.9	105.6	(88.4-125.2)	Female	17	16.7	102.1	(59.4-163.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.2	nc	(nc-nc)	Male	12	14.6	82.1	(42.4-143.4)
<u>Colon / Rectum</u>					Female	6	6.9	87.1	(31.8-189.7)
Male	48	35.7	134.3	(99.0-178.1)	<u>Ovary</u>				
Female	49	37.4	131.2	(97.0-173.4)	Female	15	11.3	132.2	(73.9-218.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.6	115.6	(55.4-212.6)	Male	18	11.6	154.9	(91.8-244.8)
Female	3	2.4	nc	(nc-nc)	Female	21	12.5	168.1	(104.0-257.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	93	104.5	89.0	(71.8-109.0)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	7.8	114.9	(52.4-218.1)
Male	15	17.6	85.0	(47.5-140.2)	Female	7	4.8	144.5	(57.9-297.7)
Female	15	10.2	146.4	(81.9-241.4)	<u>Testis</u>				
<u>Larynx</u>					Male	6	4.5	134.8	(49.2-293.3)
Male	8	5.0	159.3	(68.6-313.9)	<u>Thyroid</u>				
Female	4	1.5	nc	(nc-nc)	Male	14	7.9	177.4	(96.9-297.6)
<u>Leukemia</u>					Female	29	22.5	128.9	(86.3-185.2)
Male	13	13.4	97.2	(51.7-166.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.9	111.1	(55.4-198.8)	Female	32	27.8	115.1	(78.7-162.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	11.1	134.8	(75.4-222.4)	Male	460	429.0	107.2	(97.7-117.5)
Female	4	3.7	nc	(nc-nc)	Female	517	439.1	117.7	(107.8-128.3)
<u>Lung and Bronchus</u>									
Male	62	60.5	102.4	(78.5-131.3)					
Female	83	63.3	131.2	(104.5-162.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.9	115.8	(49.9-228.3)	Male	10	4.3	233.9	(112.0-430.2)
Female	0	2.4	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	26	21.8	119.5	(78.0-175.1)	Female	2	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.3	nc	(nc-nc)
Male	8	6.9	115.3	(49.6-227.2)	<u>Ovary</u>				
Female	6	7.1	84.1	(30.7-183.0)	Female	3	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	6	2.3	256.9	(93.8-559.3)
Female	0	0.5	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	16	20.7	77.4	(44.2-125.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.4	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.8	nc	(nc-nc)	Female	8	4.9	163.5	(70.4-322.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.2	nc	(nc-nc)	Male	80	84.8	94.3	(74.8-117.4)
Female	0	0.7	nc	(nc-nc)	Female	84	78.5	107.1	(85.4-132.6)
<u>Lung and Bronchus</u>									
Male	8	12.5	64.1	(27.6-126.4)					
Female	15	11.4	131.4	(73.5-216.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	8.0	75.2	(27.5-163.7)	Female	2	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	8.1	135.1	(67.3-241.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.5	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	26	30.0	86.5	(56.5-126.8)
Female	0	0.2	nc	(nc-nc)	Female	23	25.2	91.1	(57.8-136.8)
<u>Lung and Bronchus</u>									
Male	4	4.1	nc	(nc-nc)					
Female	1	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.3	53.6	(17.3-125.0)	Male	2	6.0	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.3	150.6	(64.8-296.8)
Female	33	33.9	97.5	(67.1-136.9)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	5	9.8	51.0	(16.4-118.9)	<u>Ovary</u>				
Female	4	9.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	29	31.1	93.3	(62.5-134.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.2	nc	(nc-nc)
Male	5	5.1	99.0	(31.9-231.0)	Female	0	1.2	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.1	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	12	7.7	154.9	(80.0-270.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	105	121.9	86.1	(70.5-104.3)
Female	0	1.0	nc	(nc-nc)	Female	100	114.3	87.5	(71.2-106.4)
<u>Lung and Bronchus</u>									
Male	17	17.1	99.4	(57.9-159.2)					
Female	13	16.4	79.3	(42.2-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	15.7	89.0	(48.6-149.3)	Male	19	8.7	218.4	(131.4-341.1)
Female	7	5.2	133.5	(53.5-275.1)	Female	10	5.6	178.9	(85.6-329.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.5	132.7	(63.5-244.1)
Female	67	46.6	143.8	(111.5-182.7)	Female	6	6.6	91.1	(33.3-198.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.7	nc	(nc-nc)
Male	13	14.4	90.0	(47.9-153.9)	<u>Ovary</u>				
Female	15	14.4	104.4	(58.4-172.2)	Female	3	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.8	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	7	5.2	135.2	(54.2-278.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	29	47.3	61.3	(41.1-88.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	2	6.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.7	nc	(nc-nc)
Male	7	5.2	133.5	(53.5-275.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.6	nc	(nc-nc)	Female	13	11.3	114.9	(61.1-196.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	144	181.2	79.5	(67.0-93.6)
Female	1	1.6	nc	(nc-nc)	Female	183	168.0	108.9	(93.7-125.9)
<u>Lung and Bronchus</u>									
Male	12	28.3	42.5	(21.9-74.2)					
Female	18	28.0	64.4	(38.1-101.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	7.4	176.5	(93.9-301.9)	Female	3	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	9.6	94.1	(42.9-178.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	35.8	83.9	(56.6-119.8)
Female	0	0.2	nc	(nc-nc)	Female	30	24.3	123.6	(83.4-176.4)
<u>Lung and Bronchus</u>									
Male	8	5.2	154.2	(66.4-303.9)					
Female	4	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	11.0	181.7	(111.0-280.7)	Male	12	7.9	151.7	(78.3-265.0)
Female	7	4.5	156.1	(62.5-321.7)	Female	6	7.0	85.3	(31.2-185.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	5	2.4	207.4	(66.8-484.0)
Female	0	2.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.1	112.4	(48.4-221.5)
Female	60	54.9	109.3	(83.4-140.7)	Female	9	6.6	137.2	(62.6-260.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	9	6.2	145.5	(66.4-276.2)
<u>Colon / Rectum</u>					Female	4	2.8	nc	(nc-nc)
Male	8	13.2	60.8	(26.2-119.9)	<u>Ovary</u>				
Female	17	14.2	119.3	(69.5-191.1)	Female	6	4.8	124.4	(45.4-270.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	47	42.1	111.7	(82.1-148.6)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.8	nc	(nc-nc)
Male	6	7.2	83.3	(30.4-181.2)	Female	4	1.8	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	6	3.6	165.1	(60.3-359.4)
<u>Leukemia</u>					Female	16	10.9	146.5	(83.7-237.9)
Male	10	5.0	201.3	(96.4-370.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.9	181.6	(72.8-374.3)	Female	19	12.2	155.9	(93.8-243.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.4	159.0	(63.7-327.6)	Male	200	160.6	124.6	(107.9-143.1)
Female	1	1.5	nc	(nc-nc)	Female	222	180.0	123.3	(107.6-140.6)
<u>Lung and Bronchus</u>									
Male	37	20.4	181.8	(128.0-250.6)					
Female	34	23.7	143.3	(99.2-200.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	11.9	150.6	(89.2-238.1)	Male	11	8.2	134.0	(66.8-239.7)
Female	9	5.6	161.8	(73.8-307.1)	Female	8	7.3	110.3	(47.5-217.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.5	237.3	(86.6-516.4)	Male	0	2.6	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	7.3	nc	(nc-nc)
Female	58	56.4	102.8	(78.0-132.9)	Female	6	7.4	80.9	(29.6-176.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	7	6.3	111.3	(44.6-229.3)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	12	13.6	88.5	(45.7-154.7)	<u>Ovary</u>				
Female	14	16.6	84.4	(46.1-141.6)	Female	5	5.1	98.0	(31.6-228.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.4	nc	(nc-nc)	Male	5	4.4	114.7	(37.0-267.6)
Female	0	1.1	nc	(nc-nc)	Female	7	5.6	124.8	(50.0-257.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	37	43.8	84.4	(59.4-116.4)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	2.9	205.9	(75.2-448.3)
Male	10	7.2	139.2	(66.6-256.0)	Female	2	2.2	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.9	nc	(nc-nc)
Male	5	2.0	248.4	(80.0-579.6)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.8	91.5	(41.8-173.7)
Male	5	5.0	100.7	(32.5-235.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.4	136.7	(49.9-297.6)	Female	12	12.6	95.2	(49.1-166.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	106.2	(34.2-247.7)	Male	179	167.1	107.1	(92.0-124.0)
Female	2	1.7	nc	(nc-nc)	Female	173	196.1	88.2	(75.6-102.4)
<u>Lung and Bronchus</u>									
Male	33	22.1	149.0	(102.6-209.3)					
Female	16	28.1	56.9	(32.5-92.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.9	nc	(nc-nc)	Male	6	3.7	162.4	(59.3-353.4)
Female	1	1.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	20	19.9	100.6	(61.4-155.3)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	0	6.1	nc	(nc-nc)	<u>Ovary</u>				
Female	7	5.2	135.1	(54.1-278.3)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	26	19.1	136.1	(88.9-199.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.5	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	75	75.5	99.3	(78.1-124.5)
Female	1	0.6	nc	(nc-nc)	Female	61	66.8	91.4	(69.9-117.4)
<u>Lung and Bronchus</u>									
Male	7	10.7	65.7	(26.3-135.3)					
Female	6	9.4	63.6	(23.2-138.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	87	72.3	120.4	(96.4-148.5)	Male	38	43.0	88.4	(62.6-121.4)
Female	36	27.9	129.1	(90.4-178.8)	Female	33	34.4	96.1	(66.1-134.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.7	85.2	(40.8-156.6)	Male	21	13.7	152.8	(94.6-233.6)
Female	14	10.3	135.3	(73.9-227.0)	Female	20	12.0	166.0	(101.4-256.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.4	nc	(nc-nc)	Male	43	38.4	112.1	(81.1-151.0)
Female	276	262.2	105.3	(93.2-118.5)	Female	56	36.5	153.6	(116.0-199.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.3	145.4	(75.0-254.0)	Male	35	28.4	123.0	(85.7-171.1)
<u>Colon / Rectum</u>					Female	13	14.9	87.4	(46.5-149.4)
Male	58	73.5	78.9	(59.9-102.0)	<u>Ovary</u>				
Female	90	84.5	106.5	(85.6-130.9)	Female	20	24.0	83.2	(50.8-128.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	17.6	73.7	(39.2-126.1)	Male	22	24.3	90.4	(56.7-136.9)
Female	3	5.3	nc	(nc-nc)	Female	33	28.6	115.5	(79.5-162.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	4.3	116.6	(37.6-272.0)	Male	252	211.4	119.2	(104.9-134.9)
Female	8	3.7	215.3	(92.7-424.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	16.2	92.6	(51.8-152.7)
Male	28	34.4	81.5	(54.1-117.7)	Female	8	11.1	72.2	(31.1-142.2)
Female	19	21.6	87.9	(52.9-137.3)	<u>Testis</u>				
<u>Larynx</u>					Male	12	7.1	168.9	(87.2-295.1)
Male	16	10.0	160.7	(91.8-260.9)	<u>Thyroid</u>				
Female	2	3.2	nc	(nc-nc)	Male	15	14.3	105.0	(58.7-173.1)
<u>Leukemia</u>					Female	43	43.5	98.9	(71.6-133.2)
Male	32	27.1	118.1	(80.8-166.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	21.4	131.0	(87.0-189.3)	Female	55	57.9	95.0	(71.6-123.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	23	21.8	105.4	(66.8-158.2)	Male	945	868.6	108.8	(102.0-116.0)
Female	9	8.2	110.3	(50.3-209.5)	Female	1031	938.7	109.8	(103.2-116.8)
<u>Lung and Bronchus</u>									
Male	122	124.3	98.1	(81.5-117.2)					
Female	161	136.5	117.9	(100.4-137.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	25.8	46.4	(24.0-81.1)
Female	0	0.2	nc	(nc-nc)	Female	10	25.3	39.6	(18.9-72.8)
<u>Lung and Bronchus</u>									
Male	0	3.5	nc	(nc-nc)					
Female	0	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.2	129.5	(80.1-197.9)	Male	12	11.1	108.1	(55.8-188.8)
Female	8	5.4	148.6	(64.0-292.8)	Female	13	9.0	143.7	(76.5-245.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	9.9	130.7	(69.5-223.6)
Female	89	72.8	122.2	(98.1-150.3)	Female	8	8.3	96.9	(41.7-190.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	11	8.5	129.6	(64.6-232.0)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	26	18.6	140.1	(91.5-205.3)	<u>Ovary</u>				
Female	24	16.9	141.9	(90.9-211.1)	Female	4	6.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.6	109.7	(35.4-256.1)	Male	4	5.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	68	59.4	114.6	(89.0-145.2)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.0	126.5	(40.8-295.1)
Male	13	9.9	131.8	(70.1-225.3)	Female	1	2.1	nc	(nc-nc)
Female	7	5.4	129.4	(51.9-266.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	6	4.7	126.8	(46.3-276.0)
<u>Leukemia</u>					Female	20	14.7	136.1	(83.1-210.2)
Male	9	6.9	130.0	(59.3-246.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.8	125.7	(45.9-273.7)	Female	17	16.6	102.4	(59.6-163.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.2	nc	(nc-nc)	Male	260	226.8	114.6	(101.1-129.4)
Female	1	1.9	nc	(nc-nc)	Female	276	231.1	119.4	(105.7-134.4)
<u>Lung and Bronchus</u>									
Male	36	29.7	121.2	(84.9-167.9)					
Female	47	29.9	157.1	(115.4-208.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	10.5	47.4	(15.3-110.7)	Male	8	7.5	107.1	(46.1-211.0)
Female	3	3.4	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.7	103.7	(41.5-213.7)
Female	52	47.6	109.2	(81.5-143.2)	Female	5	5.2	95.5	(30.8-222.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.3	nc	(nc-nc)
Male	11	12.5	87.9	(43.8-157.4)	<u>Ovary</u>				
Female	16	10.5	152.7	(87.2-248.0)	Female	2	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	5	4.0	125.1	(40.3-291.9)
Female	0	0.7	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	31	43.6	71.1	(48.3-100.9)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.6	nc	(nc-nc)
Male	5	6.9	72.1	(23.2-168.1)	Female	0	1.3	nc	(nc-nc)
Female	5	3.5	142.6	(45.9-332.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	7	3.4	208.3	(83.4-429.1)
<u>Leukemia</u>					Female	7	9.4	74.7	(29.9-153.9)
Male	5	4.6	109.8	(35.4-256.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.9	nc	(nc-nc)	Female	15	11.1	135.2	(75.6-223.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.5	nc	(nc-nc)	Male	141	156.8	89.9	(75.7-106.1)
Female	0	1.2	nc	(nc-nc)	Female	156	148.6	105.0	(89.1-122.8)
<u>Lung and Bronchus</u>									
Male	22	19.7	111.5	(69.8-168.8)					
Female	19	19.5	97.5	(58.7-152.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.3	nc	(nc-nc)	Male	11	10.2	108.2	(53.9-193.6)
Female	0	0.1	nc	(nc-nc)	Female	3	9.7	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.2	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	6	7.1	84.3	(30.8-183.6)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	13	21.0	61.9	(32.9-105.9)
Female	1	0.2	nc	(nc-nc)	Female	14	25.2	55.5	(30.3-93.1)
<u>Lung and Bronchus</u>									
Male	4	2.8	nc	(nc-nc)					
Female	0	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	6.8	73.3	(23.6-171.0)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	6.3	95.9	(35.0-208.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	23.3	73.0	(42.5-116.9)
Female	0	0.2	nc	(nc-nc)	Female	19	21.0	90.6	(54.5-141.5)
<u>Lung and Bronchus</u>									
Male	3	2.9	nc	(nc-nc)					
Female	3	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	62	54.6	113.5	(87.0-145.5)	Male	31	33.8	91.8	(62.3-130.3)
Female	26	22.3	116.8	(76.3-171.1)	Female	28	28.6	97.9	(65.0-141.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	9.6	145.4	(79.4-244.0)	Male	9	10.7	83.8	(38.2-159.0)
Female	7	8.8	79.5	(31.9-163.8)	Female	3	9.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	34	30.1	112.8	(78.1-157.6)
Female	201	222.6	90.3	(78.2-103.7)	Female	31	29.8	104.1	(70.7-147.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.0	128.1	(58.5-243.2)	Male	33	23.7	139.1	(95.7-195.3)
<u>Colon / Rectum</u>					Female	10	12.4	80.9	(38.7-148.7)
Male	55	57.3	96.1	(72.4-125.0)	<u>Ovary</u>				
Female	79	66.0	119.8	(94.8-149.3)	Female	13	20.2	64.3	(34.2-110.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	26	14.1	184.2	(120.3-270.0)	Male	20	19.0	105.5	(64.4-162.9)
Female	5	4.3	117.5	(37.9-274.2)	Female	13	22.4	58.0	(30.8-99.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.6	nc	(nc-nc)	Male	163	178.6	91.3	(77.8-106.4)
Female	2	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	12.6	63.6	(27.4-125.4)
Male	29	28.1	103.0	(69.0-148.0)	Female	9	8.6	105.2	(48.0-199.7)
Female	19	18.2	104.1	(62.7-162.6)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.2	128.1	(55.2-252.4)
Male	8	8.2	98.2	(42.3-193.4)	<u>Thyroid</u>				
Female	3	2.8	nc	(nc-nc)	Male	15	12.1	123.5	(69.1-203.8)
<u>Leukemia</u>					Female	32	37.6	85.2	(58.3-120.3)
Male	18	21.0	85.7	(50.7-135.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	17.3	46.1	(19.9-90.9)	Female	52	51.0	101.9	(76.1-133.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	18.1	94.0	(54.7-150.5)	Male	723	694.8	104.1	(96.6-111.9)
Female	6	6.8	88.0	(32.1-191.6)	Female	757	779.5	97.1	(90.3-104.3)
<u>Lung and Bronchus</u>									
Male	112	96.3	116.3	(95.8-139.9)					
Female	143	114.3	125.1	(105.4-147.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	14.8	81.2	(41.9-141.9)
Female	0	0.1	nc	(nc-nc)	Female	10	12.1	82.4	(39.4-151.5)
<u>Lung and Bronchus</u>									
Male	3	2.1	nc	(nc-nc)					
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.1	182.4	(97.0-311.9)	Male	5	5.0	100.2	(32.3-233.7)
Female	2	3.0	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	8	4.5	178.2	(76.7-351.1)
Female	39	34.8	112.0	(79.7-153.2)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.8	nc	(nc-nc)
Male	7	8.3	83.9	(33.6-172.8)	<u>Ovary</u>				
Female	12	9.4	127.5	(65.8-222.8)	Female	6	3.1	194.0	(70.9-422.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	7	2.6	265.7	(106.4-547.5)
Female	0	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	31	27.3	113.6	(77.2-161.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.8	nc	(nc-nc)
Male	10	4.5	222.5	(106.5-409.1)	Female	1	1.2	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.9	116.3	(50.1-229.1)
Male	3	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.5	276.8	(110.9-570.3)	Female	6	7.8	76.9	(28.1-167.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.8	nc	(nc-nc)	Male	130	102.5	126.9	(106.0-150.7)
Female	0	1.0	nc	(nc-nc)	Female	134	116.5	115.0	(96.4-136.2)
<u>Lung and Bronchus</u>									
Male	15	13.0	115.4	(64.5-190.3)					
Female	22	15.6	140.8	(88.2-213.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	71	65.2	108.9	(85.0-137.3)	Male	65	42.6	152.5	(117.7-194.4)
Female	19	22.9	82.8	(49.8-129.3)	Female	61	32.3	188.6	(144.2-242.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	12.7	86.7	(43.2-155.1)	Male	9	13.4	67.1	(30.6-127.3)
Female	10	10.1	98.9	(47.3-181.8)	Female	9	10.5	86.0	(39.2-163.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.3	nc	(nc-nc)	Male	49	37.9	129.2	(95.6-170.9)
Female	300	259.9	115.4	(102.7-129.3)	Female	35	32.2	108.8	(75.8-151.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	8.6	57.9	(18.7-135.2)	Male	37	31.5	117.4	(82.6-161.8)
<u>Colon / Rectum</u>					Female	14	13.8	101.7	(55.6-170.6)
Male	79	70.5	112.0	(88.7-139.6)	<u>Ovary</u>				
Female	74	68.7	107.6	(84.5-135.1)	Female	31	23.0	134.6	(91.4-191.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	18.0	116.8	(72.2-178.5)	Male	26	23.4	111.1	(72.6-162.8)
Female	1	4.5	nc	(nc-nc)	Female	21	23.0	91.2	(56.4-139.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	4.9	nc	(nc-nc)	Male	248	238.6	103.9	(91.4-117.7)
Female	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	15.4	64.9	(31.1-119.3)
Male	33	37.3	88.5	(60.9-124.3)	Female	9	8.8	102.0	(46.5-193.6)
Female	19	20.4	93.0	(55.9-145.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	8.8	57.1	(18.4-133.2)
Male	13	10.6	123.1	(65.5-210.5)	<u>Thyroid</u>				
Female	1	3.2	nc	(nc-nc)	Male	19	16.9	112.6	(67.8-175.8)
<u>Leukemia</u>					Female	70	46.2	151.6	(118.2-191.5)
Male	37	26.1	141.9	(99.9-195.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	18.5	91.8	(53.4-146.9)	Female	70	60.3	116.0	(90.4-146.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	23.3	115.8	(76.3-168.5)	Male	975	884.6	110.2	(103.4-117.4)
Female	5	7.4	67.9	(21.9-158.4)	Female	978	868.4	112.6	(105.7-119.9)
<u>Lung and Bronchus</u>									
Male	130	119.5	108.8	(90.9-129.2)					
Female	135	121.9	110.7	(92.8-131.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	11	12.2	90.0	(44.9-161.0)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.6	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.9	100.4	(53.4-171.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	38	46.1	82.4	(58.3-113.2)
Female	0	0.3	nc	(nc-nc)	Female	43	39.0	110.2	(79.8-148.5)
<u>Lung and Bronchus</u>									
Male	2	6.2	nc	(nc-nc)					
Female	6	5.4	111.8	(40.8-243.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.3	150.3	(48.4-350.8)	Male	4	2.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	16	14.6	109.9	(62.8-178.5)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	6	2.0	300.5	(109.7-654.1)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	5	4.0	125.2	(40.3-292.1)	<u>Ovary</u>				
Female	2	3.1	nc	(nc-nc)	Female	5	1.2	403.5	(130.0-941.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	20	14.4	138.9	(84.8-214.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	5	2.2	224.6	(72.4-524.2)	Female	0	0.4	nc	(nc-nc)
Female	5	1.1	473.1	(152.5-1104.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	5	2.7	183.3	(59.1-427.7)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	67	50.3	133.3	(103.3-169.3)
Female	0	0.4	nc	(nc-nc)	Female	51	44.7	114.0	(84.9-149.9)
<u>Lung and Bronchus</u>									
Male	2	6.2	nc	(nc-nc)					
Female	3	5.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	4.9	nc	(nc-nc)	Male	7	3.3	214.1	(85.8-441.1)
Female	4	1.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	19	16.3	116.4	(70.1-181.8)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	2.7	223.7	(81.7-486.9)
<u>Colon / Rectum</u>					Female	2	0.9	nc	(nc-nc)
Male	7	5.7	123.2	(49.3-253.8)	<u>Ovary</u>				
Female	8	4.7	169.0	(72.7-332.9)	Female	3	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	14	19.6	71.5	(39.0-119.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.4	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.0	nc	(nc-nc)	Male	79	69.3	113.9	(90.2-142.0)
Female	1	0.5	nc	(nc-nc)	Female	72	56.5	127.4	(99.7-160.5)
<u>Lung and Bronchus</u>									
Male	12	9.1	132.0	(68.1-230.7)					
Female	14	8.3	168.7	(92.2-283.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	91	97.3	93.5	(75.3-114.8)	Male	51	62.8	81.2	(60.4-106.7)
Female	31	36.7	84.6	(57.5-120.0)	Female	56	52.6	106.5	(80.4-138.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	18.8	95.6	(56.6-151.1)	Male	18	19.4	92.6	(54.8-146.3)
Female	14	15.9	88.0	(48.1-147.7)	Female	11	16.4	67.0	(33.4-120.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.3	nc	(nc-nc)	Male	49	56.0	87.5	(64.7-115.7)
Female	379	394.1	96.2	(86.7-106.4)	Female	60	50.9	117.9	(89.9-151.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	19	13.9	136.8	(82.3-213.6)	Male	66	43.4	152.1	(117.6-193.5)
<u>Colon / Rectum</u>					Female	22	21.3	103.4	(64.8-156.6)
Male	145	103.9	139.6	(117.8-164.2)	<u>Ovary</u>				
Female	108	110.9	97.4	(79.9-117.6)	Female	32	35.6	89.8	(61.4-126.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	28	25.0	112.0	(74.4-161.9)	Male	30	33.7	88.9	(60.0-127.0)
Female	11	7.0	156.1	(77.8-279.3)	Female	36	36.8	97.9	(68.5-135.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	8.2	97.6	(42.0-192.3)	Male	265	309.3	85.7	(75.7-96.7)
Female	8	6.7	118.8	(51.2-234.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	22.7	110.0	(71.2-162.5)
Male	47	52.0	90.4	(66.4-120.2)	Female	11	14.3	77.1	(38.4-138.0)
Female	36	31.7	113.6	(79.5-157.3)	<u>Testis</u>				
<u>Larynx</u>					Male	15	16.5	90.7	(50.7-149.6)
Male	19	14.6	130.1	(78.3-203.2)	<u>Thyroid</u>				
Female	6	4.8	125.5	(45.8-273.2)	Male	18	24.6	73.0	(43.3-115.4)
<u>Leukemia</u>					Female	69	76.8	89.9	(69.9-113.8)
Male	23	39.1	58.8	(37.3-88.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	27	29.9	90.4	(59.5-131.5)	Female	89	88.7	100.4	(80.6-123.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	63	32.3	195.0	(149.8-249.4)	Male	1318	1255.8	105.0	(99.4-110.8)
Female	14	11.4	122.5	(66.9-205.6)	Female	1374	1358.0	101.2	(95.9-106.7)
<u>Lung and Bronchus</u>									
Male	233	171.8	135.6	(118.8-154.2)					
Female	230	191.4	120.2	(105.1-136.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	34.2	102.2	(71.2-142.2)	Male	17	21.9	77.6	(45.2-124.2)
Female	7	12.7	55.1	(22.1-113.5)	Female	16	18.6	86.3	(49.3-140.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.5	92.8	(33.9-201.9)	Male	7	6.9	101.3	(40.6-208.7)
Female	4	5.8	nc	(nc-nc)	Female	10	5.8	173.1	(82.9-318.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	15	19.6	76.7	(42.9-126.5)
Female	123	144.6	85.0	(70.7-101.5)	Female	16	18.1	88.4	(50.5-143.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.0	138.8	(55.6-285.9)	Male	6	15.3	39.1	(14.3-85.1)
<u>Colon / Rectum</u>					Female	8	7.7	104.4	(44.9-205.7)
Male	39	36.7	106.3	(75.6-145.4)	<u>Ovary</u>				
Female	42	39.0	107.6	(77.5-145.4)	Female	11	12.8	86.0	(42.9-153.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.9	67.7	(24.7-147.4)	Male	11	11.8	93.1	(46.4-166.6)
Female	4	2.5	nc	(nc-nc)	Female	8	12.8	62.5	(26.9-123.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.6	nc	(nc-nc)	Male	118	109.5	107.8	(89.2-129.1)
Female	0	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.0	100.0	(43.1-197.0)
Male	21	18.3	114.6	(70.9-175.2)	Female	7	5.0	139.8	(56.0-288.1)
Female	11	11.3	97.1	(48.4-173.8)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.8	nc	(nc-nc)
Male	6	5.2	115.5	(42.2-251.4)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	9	8.4	107.3	(49.0-203.8)
<u>Leukemia</u>					Female	33	27.4	120.5	(82.9-169.2)
Male	10	13.6	73.7	(35.3-135.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	10.6	nc	(nc-nc)	Female	29	32.6	88.8	(59.5-127.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	11.6	138.3	(79.0-224.6)	Male	401	441.0	90.9	(82.2-100.3)
Female	3	4.1	nc	(nc-nc)	Female	428	486.2	88.0	(79.9-96.8)
<u>Lung and Bronchus</u>									
Male	46	60.7	75.8	(55.5-101.1)					
Female	56	66.9	83.7	(63.2-108.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.7	116.6	(66.6-189.4)	Male	4	9.1	nc	(nc-nc)
Female	7	5.1	137.7	(55.2-283.8)	Female	9	7.2	124.4	(56.7-236.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.1	111.2	(50.7-211.1)
Female	58	57.0	101.7	(77.2-131.4)	Female	8	7.2	111.6	(48.1-220.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	5	6.8	73.9	(23.8-172.4)
<u>Colon / Rectum</u>					Female	2	3.0	nc	(nc-nc)
Male	24	15.3	156.4	(100.2-232.7)	<u>Ovary</u>				
Female	20	15.3	130.3	(79.6-201.3)	Female	5	5.0	99.2	(32.0-231.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	7	4.9	142.2	(57.0-292.9)
Female	4	1.0	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	49	47.6	103.0	(76.2-136.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.3	nc	(nc-nc)
Male	13	7.9	165.5	(88.0-283.0)	Female	4	2.0	nc	(nc-nc)
Female	10	4.5	222.4	(106.5-409.0)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.9	317.1	(115.8-690.3)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.6	165.0	(60.2-359.1)
<u>Leukemia</u>					Female	24	10.6	226.1	(144.8-336.4)
Male	3	5.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.1	120.6	(38.9-281.4)	Female	14	12.9	108.8	(59.4-182.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.0	nc	(nc-nc)	Male	214	185.1	115.6	(100.6-132.2)
Female	1	1.6	nc	(nc-nc)	Female	235	192.1	122.3	(107.2-139.0)
<u>Lung and Bronchus</u>									
Male	34	24.8	136.9	(94.8-191.3)					
Female	30	27.0	111.1	(74.9-158.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	26.0	138.4	(96.9-191.7)	Male	18	16.9	106.3	(62.9-168.0)
Female	6	10.5	57.3	(20.9-124.7)	Female	13	14.2	91.3	(48.5-156.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.2	96.7	(31.1-225.6)	Male	5	5.3	93.9	(30.3-219.1)
Female	6	4.5	133.7	(48.8-291.0)	Female	4	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	15.1	119.2	(70.6-188.4)
Female	135	111.9	120.7	(101.2-142.9)	Female	8	14.3	55.8	(24.0-109.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	7	12.3	57.1	(22.9-117.6)
<u>Colon / Rectum</u>					Female	5	6.0	83.0	(26.8-193.8)
Male	28	28.1	99.7	(66.2-144.1)	<u>Ovary</u>				
Female	22	31.5	69.8	(43.7-105.7)	Female	10	10.0	100.3	(48.0-184.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.0	143.4	(68.7-263.8)	Male	7	9.2	75.9	(30.4-156.5)
Female	2	2.0	nc	(nc-nc)	Female	9	10.6	85.1	(38.8-161.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.9	nc	(nc-nc)	Male	56	88.3	63.4	(47.9-82.4)
Female	4	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.1	98.0	(35.8-213.3)
Male	13	14.5	89.7	(47.7-153.4)	Female	1	4.1	nc	(nc-nc)
Female	6	8.9	67.5	(24.6-146.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.4	174.6	(63.8-380.0)
Male	4	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	8	6.6	120.7	(52.0-237.8)
<u>Leukemia</u>					Female	28	20.0	140.2	(93.2-202.7)
Male	11	10.6	103.8	(51.8-185.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.4	130.5	(65.0-233.4)	Female	28	25.1	111.4	(74.0-161.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.1	98.8	(45.1-187.5)	Male	311	344.4	90.3	(80.6-100.9)
Female	5	3.3	153.8	(49.6-358.9)	Female	395	382.0	103.4	(93.4-114.1)
<u>Lung and Bronchus</u>									
Male	42	46.9	89.5	(64.5-121.0)					
Female	47	54.0	87.1	(64.0-115.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.5	80.0	(38.3-147.1)	Male	10	8.4	118.8	(56.9-218.5)
Female	3	3.6	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.6	92.1	(36.9-189.7)
Female	57	47.0	121.3	(91.9-157.2)	Female	7	5.4	130.0	(52.1-267.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	1	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	13	14.2	91.4	(48.6-156.3)	<u>Ovary</u>				
Female	12	10.9	109.7	(56.6-191.6)	Female	2	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	39	49.2	79.3	(56.4-108.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	8	7.7	104.2	(44.9-205.4)	Female	0	1.4	nc	(nc-nc)
Female	6	3.5	172.0	(62.8-374.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.5	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.1	87.8	(37.8-173.0)
Male	4	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	16	11.0	146.0	(83.4-237.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.8	nc	(nc-nc)	Male	139	177.6	78.3	(65.8-92.4)
Female	2	1.2	nc	(nc-nc)	Female	161	149.5	107.7	(91.7-125.7)
<u>Lung and Bronchus</u>									
Male	26	22.8	114.0	(74.4-167.0)					
Female	19	19.6	96.9	(58.3-151.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	47.8	104.6	(77.7-138.0)	Male	23	32.5	70.8	(44.8-106.2)
Female	16	19.7	81.2	(46.4-131.8)	Female	27	28.3	95.5	(62.9-139.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.3	106.7	(53.2-190.9)	Male	6	9.8	61.2	(22.3-133.2)
Female	11	8.6	127.9	(63.8-228.8)	Female	11	8.8	125.0	(62.3-223.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	31	29.0	106.9	(72.7-151.8)
Female	208	213.8	97.3	(84.5-111.4)	Female	27	27.5	98.3	(64.7-143.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	7.5	nc	(nc-nc)	Male	22	23.1	95.3	(59.7-144.2)
<u>Colon / Rectum</u>					Female	16	11.4	139.8	(79.9-227.1)
Male	67	53.3	125.7	(97.4-159.6)	<u>Ovary</u>				
Female	45	59.8	75.3	(54.9-100.8)	Female	17	19.1	89.0	(51.8-142.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	12.6	87.1	(43.4-155.9)	Male	23	16.9	135.8	(86.1-203.8)
Female	5	3.8	130.9	(42.2-305.6)	Female	17	19.9	85.6	(49.8-137.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	4.7	107.2	(34.5-250.2)	Male	116	158.0	73.4	(60.6-88.0)
Female	4	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	20	11.5	174.5	(106.6-269.5)
Male	35	27.4	127.6	(88.8-177.4)	Female	8	7.7	103.9	(44.7-204.7)
Female	32	17.1	187.2	(128.0-264.2)	<u>Testis</u>				
<u>Larynx</u>					Male	7	9.5	73.9	(29.6-152.3)
Male	10	7.4	134.8	(64.5-247.9)	<u>Thyroid</u>				
Female	9	2.5	353.9	(161.5-671.9)	Male	11	13.9	79.4	(39.6-142.1)
<u>Leukemia</u>					Female	44	41.2	106.9	(77.7-143.5)
Male	31	20.3	152.7	(103.7-216.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	16.2	68.0	(33.9-121.7)	Female	35	47.7	73.3	(51.1-102.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	27	16.9	160.0	(105.4-232.8)	Male	683	642.7	106.3	(98.5-114.6)
Female	6	6.2	96.9	(35.4-210.9)	Female	742	733.0	101.2	(94.1-108.8)
<u>Lung and Bronchus</u>									
Male	127	85.0	149.4	(124.6-177.8)					
Female	139	103.2	134.7	(113.2-159.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	3.0	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	5	9.4	53.3	(17.2-124.5)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	13	9.6	135.6	(72.1-231.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	27	36.0	75.1	(49.4-109.2)
Female	0	0.3	nc	(nc-nc)	Female	17	32.1	52.9	(30.8-84.7)
<u>Lung and Bronchus</u>									
Male	2	5.3	nc	(nc-nc)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	6.0	nc	(nc-nc)	Male	5	3.9	127.6	(41.1-297.8)
Female	4	2.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	24	24.0	100.1	(64.1-148.9)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	7	6.5	107.9	(43.2-222.4)	<u>Ovary</u>				
Female	8	6.4	124.5	(53.6-245.4)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	23	22.6	101.9	(64.6-152.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.2	nc	(nc-nc)	Male	78	82.4	94.7	(74.8-118.2)
Female	0	0.7	nc	(nc-nc)	Female	65	80.2	81.1	(62.6-103.3)
<u>Lung and Bronchus</u>									
Male	13	11.0	117.7	(62.6-201.3)					
Female	3	10.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	17.6	119.0	(73.6-181.9)	Male	15	11.8	127.1	(71.1-209.7)
Female	11	7.2	152.7	(76.1-273.2)	Female	17	10.0	169.3	(98.5-271.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.6	164.9	(60.2-359.0)	Male	3	3.6	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.5	114.4	(59.1-199.9)
Female	81	79.5	101.9	(81.0-126.7)	Female	16	10.1	158.6	(90.6-257.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	12	8.8	136.1	(70.3-237.8)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	25	19.5	128.2	(82.9-189.2)	<u>Ovary</u>				
Female	25	21.5	116.4	(75.3-171.9)	Female	4	7.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.9	122.6	(44.8-266.9)	Male	8	6.4	125.2	(53.9-246.7)
Female	1	1.4	nc	(nc-nc)	Female	7	7.2	96.8	(38.8-199.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	71	65.3	108.7	(84.9-137.1)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.2	nc	(nc-nc)
Male	13	10.3	126.0	(67.0-215.5)	Female	7	2.7	255.3	(102.3-526.1)
Female	16	6.3	252.1	(144.0-409.4)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.8	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	22	14.3	154.0	(96.5-233.2)
Male	14	7.2	194.3	(106.1-326.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	5.8	206.5	(106.6-360.7)	Female	24	18.4	130.8	(83.8-194.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.5	76.6	(24.7-178.8)	Male	282	243.6	115.8	(102.6-130.1)
Female	3	2.3	nc	(nc-nc)	Female	328	269.1	121.9	(109.1-135.8)
<u>Lung and Bronchus</u>									
Male	34	32.4	104.9	(72.6-146.6)					
Female	48	38.5	124.8	(92.0-165.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.4	97.1	(50.1-169.6)	Male	10	7.3	136.7	(65.4-251.4)
Female	2	4.7	nc	(nc-nc)	Female	7	5.5	127.6	(51.1-262.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	45	44.1	102.1	(74.5-136.6)	Female	5	6.1	82.5	(26.6-192.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	6	5.0	120.6	(44.0-262.5)
<u>Colon / Rectum</u>					Female	6	2.5	240.5	(87.8-523.5)
Male	10	12.3	81.2	(38.9-149.3)	<u>Ovary</u>				
Female	8	13.8	58.1	(25.0-114.4)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.8	104.9	(33.8-244.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	40	39.8	100.5	(71.8-136.9)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.8	nc	(nc-nc)
Male	8	6.0	134.4	(57.9-264.9)	Female	2	1.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.4	78.5	(25.3-183.2)
Male	2	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	7	10.2	68.9	(27.6-142.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.0	nc	(nc-nc)	Male	139	151.8	91.6	(77.0-108.1)
Female	1	1.4	nc	(nc-nc)	Female	128	156.2	82.0	(68.4-97.5)
<u>Lung and Bronchus</u>									
Male	17	22.1	77.0	(44.8-123.2)					
Female	7	23.7	29.5	(11.8-60.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	10.7	65.2	(26.1-134.4)
Female	0	0.1	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.6	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.5	128.4	(51.4-264.6)	Male	4	3.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	6	3.4	178.9	(65.3-389.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	27	27.2	99.4	(65.5-144.6)	Female	3	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	6	6.4	93.9	(34.3-204.4)	<u>Ovary</u>				
Female	6	6.8	88.8	(32.4-193.2)	Female	4	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.7	nc	(nc-nc)	Male	5	2.1	235.2	(75.8-549.0)
Female	0	0.4	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	26	24.4	106.7	(69.7-156.4)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.2	134.9	(54.1-278.0)
Male	3	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.8	nc	(nc-nc)	Female	5	6.2	80.7	(26.0-188.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.4	nc	(nc-nc)	Male	78	83.2	93.8	(74.1-117.1)
Female	0	0.7	nc	(nc-nc)	Female	87	86.9	100.1	(80.2-123.5)
<u>Lung and Bronchus</u>									
Male	7	10.5	66.7	(26.7-137.4)					
Female	5	11.2	44.7	(14.4-104.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	8	5.0	160.7	(69.2-316.7)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	5.1	138.6	(55.5-285.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	18	18.5	97.3	(57.6-153.7)
Female	0	0.1	nc	(nc-nc)	Female	19	15.9	119.5	(71.9-186.6)
<u>Lung and Bronchus</u>									
Male	3	2.4	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;